LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (23rd October 2018) - Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; et al.